Mitazalimab
Phase 3Monoclonal antibody
Mitazalimab is one of 96 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Mitazalimab
UUniversity of Pennsylvania
Phase 3
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Sulfonylureas
Eli LillyPreclinical
Active Comparator
ModernaPreclinical
PEG-Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer1 trial
Combination Therapy1 trial
MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Completed·—·Phase 1·NCT05650918·22 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mitazalimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Pennsylvania